Протиепілептичні лікарські засоби  як об'єкти національного фармацевтичного ринку.  Повідомлення II.  Аналіз економічної доступності  протиепілептичних лікарських засобів  (на прикладі асортиментних пропозицій  топ-3 оптових фармацевтичних підприємств України

Pavlo Genyk; Oxana Levitsky; Iryna Chukhray; Nataly Yarko; Sophia Tereschuk; Bogdan Hromovik

doi:10.5281/zenodo.10255880

Authors

Pavlo Genyk Lviv National Medical University named after Daniil Galitsky, Ukraine
Oxana Levitsky Lviv National Medical University named after Daniil Galitsky, Ukraine
Iryna Chukhray Lviv National Medical University named after Daniil Galitsky, Ukraine
Nataly Yarko Lviv National Medical University named after Daniil Galitsky, Ukraine
Sophia Tereschuk Lviv Medical Academy named after Andriy Krupinsky, Ukraine
Bogdan Hromovik Lviv National Medical University named after Daniil Galitsky, Ukraine

DOI:

https://doi.org/10.5281/zenodo.10255880

Abstract

Introduction. Epilepsy is one of the most common neurological diseases in the world and requires appropriate medical treatment. The Global Burden of Epilepsy Report estimates that there are 13 million disability adjusted life years due to epilepsy each year. Epilepsy is an important medical, social and economic problem of modern society, the solution of which is often based on the use of antiepileptic drugs. According to the State Strategy for the implementation of the state policy of providing the population with medicines for the period until 2025, the cost of medicines is an important factor that ensures their financial availability for the population. This determined the relevance of this stage of the research.

Material & methods. Materials: information about purchase prices (P_p) for antiepileptic drugs of wholesale pharmaceutical enterprises (WPE 1, WPE 2 and WPE 3), which at the time of the study were in the TOP-3 in terms of the volume of drug supplies to pharmacies.

Methods: information search, comparison, analysis, generalization, determination of the cost of defined daily dose (DDD). The study period was February 2023.

Results & discussion. It was found that at the time of the research, the TOP-3 WPE offered 105 assortment items (AI) of 11 international non-proprietary names of antiepileptic drugs in their price lists, taking into account the dosage forms and doses. By studying the DDD P_p of antiepileptic drugs AI, it was established that the largest number of AI with the lowest DDD P_p was offered by WPE 1 – 34 AI (or 32.38% of the total number of analyzed drugs). At the same time, in 26 AI (24.76%) offered by WPE 2, the cost of DDD was lower than that of competitors. The most valuable were the offers of WPE 3. It was found that among the 36 AI of pregabalin, the lowest DDD P_p was inherent in 15 and 8 AI, offered by WPE 1 and WPE 2, respectively. The price range of AI pregabalin DDD ranged from UAH 18.60 (“Pregabalin-Darnytsia”, capsules 300 mg No. 21, PJSC Pharmaceutical company Darnytsia (Ukraine), the lowest price offer of WPE 1) to UAH 58.28 (“Galara”, capsules 75 mg No. 14, WORLD MEDICINE İLAÇ SAN. VE TİC. A.Ş. (Turkey), the highest price offer of WPE 3). The calculated values of Cliq ranging from 0.002 to 0.17 and Iаv from 5.68% to 17.21% for AI of pregabalin indicate a high level of competition and relative economic availability of the analyzed antiepileptic drugs in the studied segment of the wholesale market. At the same time, using the matrix projection of the integrated Sliq / Iav analysis, 7 or 19.44% of pregabalin AI were determined, which were the most economically available in the TOP-3 offers of the WPE. Conclusion. A situational analysis of the economic availability of antiepileptic drugs was carried out on the example of assortment offers of the TOP-3 wholesale pharmaceutical enterprises of Ukraine.

Keywords: Еpilepsy, antiepileptic drugs, wholesale pharmaceutical enterprises, cost of DDD, price liquidity ratio, indicator of economic availability

References

Singh G., Sander J. W. The global burden of epilepsy report: Implications for low- and middle-income countries. Epilepsy & Behavior. 2020. 105. 106949. URL: https://www.sciencedirect.com/science/article/abs/pii/S1525505019314155.

Jyonouchi H., Geng L. Intractable epilepsy (IE) and responses to anakinra, a human recombinant IL-1 recrptor agonist (IL-1ra): case reports. J Clin Cell Immunol. 2016. 7. P. 1-5. DOI:10.4172/2155-9899.1000456.

Riva A., Golda A., Balagura G. et al. New Trends and Most Promising Therapeutic Strategies for Epilepsy Treatment. Front Neurol. 2021. 12. Article 753753. doi: 10.3389/fneur.2021.753753.

Epilepsy: A public health imperative. Geneva: World Health Organization; 2019. URL: https://www.ilae.org/about-ilae/policy-and-advocacy/international-public-policy-activities/global-epilepsy-report-2019.

Epilepsy – World Health Organization (WHO), 2022. URL: https://www.who.int/news-room/fact-sheets/detail/epilepsy.

Begley C. E., Durgin T. L. The direct cost of epilepsy in the United States: A systematic review of estimates. Epilepsia. 2015. 56 (9). P. 1376-1387. doi: 10.1111/epi.13084.

Kobau R., Zahran H., Thurman D. J. et al. Epilepsy surveillance among adults-19 States, Behavioral Risk Factor Surveillance System, 2005. MMWR Surveill Summ. 2008. 57 (6). P. 1-20. URL: https://pubmed.ncbi.nlm.nih.gov/18685554/.

Fishman J., Shrestha S., Wang L. et al. Impact of Medicaid antiepileptic drug formulary restrictions on health outcomes and costs (P6.279). American Academy of Neurology 70thAnnual Meeting. Los Angeles, CA. April 21-27, 2018. URL: https://n.neurology.org/content/90/15_Supplement/P6.279.

Epilepsy Research at the National Institutes of Health. Epilepsy Foundation, 2017. URL: https://www.epilepsy.com/stories/epilepsy-research-national-institutes-health.

Examining the Economic Impact and Implications of Epilepsy. AJMC, 2020. URL: https://www.ajmc.com/view/examining-the-economic-impact-and-implications-of-epilepsy.

Cramer J. A., Wang Z. J., Change E. et al. Healthcare utilization and costs in adults with stable and uncontrolled epilepsy. Epilepsy Behav. 2014. 31. P. 356-362. doi: 10.1016/j.yebeh.2013.09.046.

Joyce N. R., Fishman J., Green S. et al. Cost Sharing for Antiepileptic Drugs: Medication Utilization and Health Plan Costs. AJMC. 2018. 24 (6): e183-e189. URL: https://www.ajmc.com/view/cost-sharing-for-antiepileptic-drugs-medication-utilization-and-health-plan-costs.

Terman S. W., Lin Ch. C., Kerr W. T. et al. Changes in the Use of Brand Name and Generic Medications and Total Prescription Cost Among Medicare Beneficiaries With Epilepsy. Neurology. 2022. 99 (8). e751-e761; DOI: 10.1212/WNL.0000000000200779.

Begley Ch., Wagner R. G., Abraham A. et al. The global cost of epilepsy: A systematic review and extrapolation. Epilepsia. 2022. 63 (4). P. 892-903. doi.org/10.1111/epi.17165.

Academy of Science of South Africa. Proceedings report Changing patterns of Non-Communicable Diseases. 2013. URL: https://research.assaf.org.za/handle/20.500.11911/53.

Al-Zakwani I., Hanssens Y., Deleu D. et al. Annual direct medical cost and contributing factors to total cost of Epilepsy in Oman. Seizure. 2003. 12(8). P.555–560. doi:10.1016/S1059-1311(03)00068-2.

Gao L., Xia L., Pan S-Q. et al. Burden of Epilepsy: a prevalence-based cost of illness study of direct, indirect and intangible costs for Epilepsy. Epilepsy Res. 2015. 110. P.146–156. doi:10.1016/j.eplepsyres.2014.12.001.

Riechmann J., Strzelczyk A., Reese J. P. et al. Costs of Epilepsy and cost‐driving factors in children, adolescents, and their caregivers in Germany. Epilepsia. 2015. 56(9). P.1388–1397. doi:10.1111/epi.13089.

Melkamu P., Animut Y., Minyihun A. et al. Cost of Illness of Epilepsy and Associated Factors in Patients Attending Adult Outpatient Department of University of Gondar Referral Hospital, Northwest Ethiopia. Risk Manag Healthc Policy. 2021. 14. Р. 2385-2394. URL: https://doi.org/10.2147/RMHP.S289113.

Asghar M. A., Rehman А. А., Raza M. L. et al. Analysis of treatment adherence and cost among patients with epilepsy: a four-year retrospective cohort study in Pakistan. BMC Health Serv Res. 2021 Jan 19;21(1):72. doi: 10.1186/s12913-021-06085-0.

Singh K., Setia R. K., Sharma S. et al. Antiepileptic Drug Prices, Availability and Affordability in a Resource-Limited Setting. Ann Indian Acad Neurol. 2020 Sep-Oct; 23(5). P.674-680. doi: 10.4103/aian.AIAN_264_19.

Cameron A., Bansal A., Dua T. et al. Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries. Epilepsia. 2012. Vol. 53, Is. 6. P. 962-969. https://doi.org/10.1111/j.1528-1167.2012.03446.x.

Foster E., Chen Zh., Zomer E. et al. The costs of epilepsy in Australia. A productivity-based analysis. Neurology Dec. 2020. Vol. 95 (24) e3221-e3231. DOI: 10.1212/WNL.0000000000010862.

Bhat E. A., Dar M. A., Sidiqui P. A. L., Jabeen F. Cost of illness of epilepsy per patient per year in a tertiary care hospital in New Delhi: A Prospective Observational study. Asian Journal of Medical Sciences. 2021. 12(6). P. 79–84. URL: https://doi.org/10.3126/ajms.v12i6.36558.

Draft intersectoral global action plan on epilepsy and other neurological disorders 2022 – 2031. WHO. A75/10 Add.4. URL: https://apps.who.int/gb/ebwha/pdf_files/WHA75/A75_10Add4-en.pdf.

Henyk P. R., Levytska О. R., Chukhraу I. L. et al. Antiepileptic drugs as objects of the national pharmaceutical market. Message І. Characteristics of the nomenclature of antiepileptic drugs from the point of view of the state guarantee program of medical care of the population. Annals of Mechnikov Institute. 2023.

On the approval of the State strategy for the implementation of the state policy of providing the population with medicines for the period until 2025: Resolution of the CMU, December 5, 2018 No. 1022. URL: https://www.kmu.gov.ua/npas/pro-zatverdzhennarskimi-zasobami-na-period-do-2025-roku.

Pharmacy sales according to the results of the 1st quarter of 2023. URL: https://www.apteka.ua/article/664015.

Samsonov V.V., Silvestrov A.M., Tachynina O.M. Methodology of scientific research and examples of its use. K.: NUHT, 2022. 385 p. URL: https://ela.kpi.ua/bitstream/123456789/47687/1/MND.pdf.

Levytska О. R., Hromovyk B. P. Multifactorial analysis of drug consumption for treatment of acute disorders of cerebral circulation (scientific and methodical recommendations). Lviv: Liga-Press, 2017. 40 р.

Hromovyk B. P., Hasyuk H. D., Levytska O. R. Management and marketing in pharmacy. Textbook. Kyiv: Medicine, 2008. 752 p.

Matviychuk M. E., Hromovyk B. P. Research of assortment and price condition of the regional market of antidepressants for treatment of women in prenatal and postnatal periods. Pharmaceutical Journal. 2021. Т. 76, № 4. С. 55-63. DOI: https://doi.org/10.32352/0367-3057.4.21.05.

Amounts of the minimum wage. URL: https://services.dtkt.ua/catalogues/indexes/2.

The norm of working hours is 2023. URL: https://www.buhoblik.org.ua/kadry-zarplata/vremya/4282-norma-trivalosti-robochogo-chasu-2023.html.

ATC/DDD Index 2023. WHO Collaborating Centre for Drug Statistics Methodology. URL: https://www.whocc.no/atc_ddd_index/.